Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Creo Medical ( (GB:CREO) ) has provided an update.
Creo Medical Group plc announced the retirement of John Bradshaw, its Senior Independent Non-Executive Director, who has been with the company since its IPO in 2016. Ivonne Cantu will temporarily chair the Audit Committee until a permanent replacement is found, while Brent Boucher will take over as the Remuneration Committee chair. These changes are part of Creo’s ongoing efforts to strengthen its governance framework as it continues to innovate in the field of minimally invasive surgical endoscopy.
More about Creo Medical
Creo Medical Group plc is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices. The company focuses on enhancing surgical endoscopy for pre-cancer and cancer patients through its advanced CROMA technology powered by Kamaptive, which integrates multi-modal energy sources to improve surgical precision and patient outcomes.
Average Trading Volume: 1,257,002
Technical Sentiment Signal: Sell
Current Market Cap: £41.87M
Learn more about CREO stock on TipRanks’ Stock Analysis page.